A Phase 2, Open-Label Study of Intravenous Pevonedistat in Combination With Oral Decitabine and Cedazuridine in Adult Patients With Higher-Risk Myelodysplastic Syndromes
Latest Information Update: 30 Sep 2021
At a glance
- Drugs Pevonedistat (Primary) ; Cedazuridine; Decitabine
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms PEVOBINE
- Sponsors Takeda
- 23 Sep 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 09 Aug 2021 New trial record